Brief: FDA Grants 'Orphan Drug' Status To PharmaTher's Ketamine For Prevention Of Ischemia-Reperfusion Injury From Organ Transplantation
15/12/2022 14:11
Dec 15 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED
TO
KETAMINE FOR PREVENTION OF ISCHEMIA-REPERFUSION INJURY FROM
ORGAN TRANSPLANTATION
Source text for Eikon: ID:nGNX1pGQnT
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application